spacer
home > ict > winter 2020 > security, compliance, and control
PUBLICATIONS
International Clinical Trials

Security, Compliance, and Control




The whole pharmaceutical world is built upon a foundation of intellectual property (IP) and personally identifiable information. Without the masses of data collected from clinical trials, groundbreaking drug formulas, and research, it is easy to see how some of the top global pharma organisations would no longer be at the top of the game, highlighting just how valuable all this information is.

In 2018, the pharma industry was estimated at an astonishing $1.11 trillion, with this set to rise to $1.43 trillion by 2020. While regulatory compliance is no new thing for pharma companies, the introduction of the EU GDPR back in May 2018 means that any organisation found to be in breach of EU citizens’ data could be fined up to €20 million, or 4% of their global turnover. For a pharma company with a turnover of $30 billion, this could be a fine of $1.2 billion, which would blow the current GDPR record fine (€50 million for Google) out of the water.

As with anything, the monetary loss of a data breach is just the tip of the iceberg. Following a fine for a breach of regulatory compliance is a hugely damaged reputation and a very valuable potential loss of revenue-making IP and trade secrets.



Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Georgina Stockley is the Marketing Communications Manager at Boldon James, whose experience is in the financial services and technology sectors. Having seen first-hand the damage that can be caused by a lack of proper data protection within an organisation, Georgina is passionate about helping others understand how implementing simple solutions can have the biggest impact on their businesses.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Three-tiered, mobile-app driven program tracks individuals’ physical and psychological symptoms from COVID-19

RALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement